nDatalyze Corp. (“NDAT” or the “Corporation”) (CSE:NDAT) (OTC:NDATF) begins a Clinical Study process.
Calgary, Alberta – July 10, 2023
For Immediate Release – nDatalyze Corp. (“NDAT” or the “Corporation”) (CSE:NDAT) (OTCQB:NDATF) announces that it has filed a Clinical Study application with Mitacs, a national not-for-profit organization that empowers partnerships that deliver solutions to the world’s most pressing problems, and assists organizations in reaching their goals, funds cutting-edge innovation and creates job opportunities for students and postdoctoral fellows. The Clinical Study is being undertaken to test and validate the Corporation’s YMI predictive mental health clinical decision support system (“CDSS”), is expected to take between 6-12 months and be funded by existing cash reserves. Mitacs typically shares costs but the ratio cannot be known until a Principal Investigator is contracted and sets out the process and protocols. The posting can be seen at: https://www.mitacs.ca/en/opportunity/7921/view.
Mitacs empowers Canadian innovation through effective partnerships that deliver solutions to our most pressing problems. For over 20 years, Mitacs has assisted organizations in reaching their goals, has funded cutting-edge innovation, and has created job opportunities for students and postdocs. We are committed to driving economic growth and productivity and to creating meaningful change to improve quality of life for all Canadians. Our mission is to build a world-class, diverse community of innovators through our collaborative model, attracting and deploying top talent to industry, and matching need with expertise to create ambitious solutions to real-world challenges. We believe that increasing Canada’s productivity and prosperity will be driven by successful innovation and we’re passionate about developing the next generation of researchers who will work to fuel Canada’s knowledge-based economy. Discover us at https://www.mitacs.ca
YMI uses evidence-based, objective data from whole life experiences to predict individual mental states over time and applies this knowledge towards a fuller understanding of how mental health develops and to improve mental wellbeing. After registering at ymihealth.ca users are given access to a private, in-depth survey that applies artificial intelligence using a person’s genetic expressions, childhood environment, habits, phobias, lived experiences and lifestyle. Upon completion of the survey, YMI generates a personalized graphic report predicting a person’s predisposition for seven mental conditions including anxiety, depression, post-traumatic stress disorder, obsessive compulsive disorder, alcoholism, and personality disorders both current and forward in time. The downloadable report may be used for reference as the user considers changes to their lifestyle that may help improve their mental wellbeing and mental health journey. The service also helps connect users with therapists who are prepared to help with next steps, providing further clarity and treatment as required.
About nDatalyze Corp.:
nDatalyze Corp. generates technology-based, health-related solutions. It’s machine-learning processed, online consumer mental health application known as “YMI” is based on the Corporation’s proprietary Reference Database consisting of >1200 biometric records complete with associated electroencephalogram (“EEG”) data. YMI has only recently begun its initial staged launch and accordingly the Corporation cannot accurately predict if or when this application will become a profit generator.
FOR FURTHER INFORMATION, PLEASE CONTACT:
James Durward, President and CEO
Telephone: (403) 689-3901
Email: [email protected]
YMI Website: https://ymihealth.ca
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.
The information in this news release includes certain information and statements about management’s view of future events, expectations, plans and prospects that constitute forward looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward looking statements. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Corporation believes that the expectations reflected in forward looking statements are reasonable, it can give no assurances that the expectations of any forward-looking statements will prove to be correct. Except as required by law, the Corporation disclaims any intention and assumes no obligation to update or revise any forward looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward looking statements or otherwise.